title: [Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature].
abstract: Aripiprazole is indicated for the treatment of schizophrenia in Europe and the United States, and for bipolar disorders in the latter. Nevertheless, a review of recent literature has shown that aripiprazole has been studied in many other disorders, notably resistant depression, anxiety, obsessive-compulsive disorder, borderline personality, Tourette syndrome, addiction, psychotic symptoms in children and adolescents, and neurological and psychiatric disorders in the elderly (late onset delusional disorders, Alzheimer, Parkinson, and delirium). The study of aripiprazole in these numerous indications is motivated by its excellent tolerance and original pharmacological effect (partial agonistic effect on the D2 and 5-HT1A receptors, and antagonistic effect on the 5-HT2A receptors). This paper reviews the recent literature, with particular attention paid to the level of proof provided by these various studies.
authors.affiliation: Service de psychiatrie de l'adolescent, centre hospitalier, B.P. 29, 68250 Rouffach, France. ma.crocq@ch-rouffach.fr
authors.forename: M-A
authors.initials: MA
authors.lastname: Crocq
authors.forename: V
authors.initials: V
authors.lastname: Camus
authors.forename: B
authors.initials: B
authors.lastname: Millet
authors.forename: J
authors.initials: J
authors.lastname: Gliskman
authors.forename: J-M
authors.initials: JM
authors.lastname: Azorin
authors.forename: M-O
authors.initials: MO
authors.lastname: Krebs
authors.forename: F
authors.initials: F
authors.lastname: Limosin
authors.forename: J
authors.initials: J
authors.lastname: Costentin
authors.forename: J
authors.initials: J
authors.lastname: Daléry
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole; D001883:Borderline Personality Disorder / Q000188:drug therapy; D003865:Major Depressive Disorder / Q000188:drug therapy; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000503:physiopathology*; D010300:Parkinson Disease / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use*; D015363:Quinolones / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy; D019966:Substance-Related Disorders / Q000188:drug therapy; D005879:Tourette Syndrome / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole